These outcomes established that liraglutide was capable of alleviating high-fat diet-induced hepatic steatosis by suppressing NLRP3 inflammasome stimulation, providing a lead that liraglutide is a potential agent which may reverse the pathological characteristics of NAFLD [13]. Here, NLRP3 is linked to metabolic dysfunction-associated steatotic liver disease.